Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

KLK14 Inhibitors

KLK14 inhibitors belong to a specific category of chemical compounds designed to target and inhibit the activity of KLK14, which stands for Kallikrein-related peptidase 14. KLK14 is a member of the kallikrein-related peptidase family of serine proteases, which are enzymes that play important roles in various physiological and pathological processes. KLK14 is primarily expressed in the skin and is involved in the proteolytic cleavage of proteins, including those involved in skin barrier function, inflammation, and tissue remodeling. Inhibitors of KLK14 are primarily developed for research purposes, serving as essential tools for scientists and researchers to investigate the molecular mechanisms and functions associated with this protease and its involvement in skin biology and other biological processes. Typically, KLK14 inhibitors are small molecules or chemical compounds designed to interact with the active site of the KLK14 enzyme, thereby inhibiting its proteolytic activity. By inhibiting KLK14, these compounds can modulate the proteolytic processing of specific protein substrates, potentially affecting downstream cellular processes and signaling pathways. Researchers use KLK14 inhibitors in laboratory settings to manipulate the proteolytic activities of this enzyme and to study its roles in skin physiology, inflammation, and tissue remodeling. These inhibitors provide valuable insights into the mechanisms by which KLK14 influences various biological processes, contributing to a deeper understanding of its significance in cellular biology and tissue homeostasis. While KLK14 inhibitors may have broader implications, their primary purpose is to assist scientists in deciphering the molecular intricacies of KLK14-mediated proteolysis and its role in biological processes.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Flavopiridol

146426-40-6sc-202157
sc-202157A
5 mg
25 mg
$78.00
$259.00
41
(3)

A cyclin-dependent kinase inhibitor that may nonspecifically reduce transcription of various genes, potentially including KLK14.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$37.00
$69.00
$109.00
$218.00
$239.00
$879.00
$1968.00
47
(1)

A compound from turmeric that has been shown to modulate various signaling pathways, which could influence KLK14 expression.

Resveratrol

501-36-0sc-200808
sc-200808A
sc-200808B
100 mg
500 mg
5 g
$80.00
$220.00
$460.00
64
(2)

Acts on multiple targets in cells and could alter the transcription of a variety of genes, possibly affecting KLK14 levels.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

A polyphenol in green tea that may influence gene expression and protein activity, potentially impacting KLK14 expression.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

An inhibitor of MEK, which could lead to downstream effects on gene expression, potentially reducing KLK14 levels.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK signaling and could indirectly affect transcription factors that regulate KLK14 expression.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

PI3K inhibitor that may disrupt signaling pathways influencing KLK14 expression.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

A potent PI3K inhibitor that may have indirect effects on gene expression, including that of KLK14.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Inhibits mTOR signaling, which may reduce protein synthesis globally, potentially affecting KLK14 expression.

Chetomin

1403-36-7sc-202535
sc-202535A
1 mg
5 mg
$186.00
$674.00
10
(1)

Disrupts hypoxia-inducible factor (HIF) signaling, which may affect KLK14 expression in hypoxic environments.